Abstract:The discovery of novel therapeutic compounds through de novo drug design represents a critical challenge in the field of pharmaceutical research. Traditional drug discovery approaches are often resource intensive and time consuming, leading researchers to explore innovative methods that harness the power of deep learning and reinforcement learning techniques. Here, we introduce a novel drug design approach called drugAI that leverages the Encoder–Decoder Transformer architecture in tandem with Reinforcement Learning via a Monte Carlo Tree Search (RL-MCTS) to expedite the process of drug discovery while ensuring the production of valid small molecules with drug-like characteristics and strong binding affinities towards their targets. We successfully integrated the Encoder–Decoder Transformer architecture, which generates molecular structures (drugs) from scratch with the RL-MCTS, serving as a reinforcement learning framework. The RL-MCTS combines the exploitation and exploration capabilities of a Monte Carlo Tree Search with the machine translation of a transformer-based Encoder–Decoder model. This dynamic approach allows the model to iteratively refine its drug candidate generation process, ensuring that the generated molecules adhere to essential physicochemical and biological constraints and effectively bind to their targets. The results from drugAI showcase the effectiveness of the proposed approach across various benchmark datasets, demonstrating a significant improvement in both the validity and drug-likeness of the generated compounds, compared to two existing benchmark methods. Moreover, drugAI ensures that the generated molecules exhibit strong binding affinities to their respective targets. In summary, this research highlights the real-world applications of drugAI in drug discovery pipelines, potentially accelerating the identification of promising drug candidates for a wide range of diseases.

Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4

Artificial Intelligence-Assisted Optimization of Antipigmentation Tyrosinase Inhibitors: De Novo Molecular Generation Based on a Low Activity Lead Compound

Deep Lead Optimization: Leveraging Generative AI for Structural Modification

Artificial Intelligence in De novo Drug Design: Are We Still There?

De novo generation of dual-target ligands using adversarial training and reinforcement learning

Modern hit-finding with structure-guided de novo design: identification of novel nanomolar adenosine A2A receptor ligands using reinforcement learning

Modern hit-finding with structure-guided de novo design: identification of novel nanomolar A2A receptor ligands using reinforcement learning

De Novo Structure-Based Drug Design Using Deep Learning

Molecular Design in Synthetically Accessible Chemical Space via Deep Reinforcement Learning

Molecular generation strategy and optimization based on A2C reinforcement learning in de novo drug design

De novo design of protein target specific scaffold-based Inhibitors via Reinforcement Learning

Learning To Navigate The Synthetically Accessible Chemical Space Using Reinforcement Learning

Widely Used and Fast De Novo Drug Design by a Protein Sequence-Based Reinforcement Learning Model

AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2

De Novo Drug Design Against SARS-CoV-2 Protein Targets Using SMILES-based Deep Reinforcement Learning.

Combining generative artificial intelligence and on-chip synthesis for de novo drug design

Molecular De Novo Design through Deep Reinforcement Learning

Tuning artificial intelligence on the de novo design of natural-product-inspired retinoid X receptor modulators

De Novo Drug Design Using Transformer-Based Machine Translation and Reinforcement Learning of an Adaptive Monte Carlo Tree Search

Retro Drug Design: From Target Properties to Molecular Structures

Generation of Rational Drug-Like Molecular Structures Through a Multiple-Objective Reinforcement Learning Framework